Plavix
Product Images NDC 53808-0763

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Plavix (NDC 53808-0763). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by State Of Florida Doh Central Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (75 mg 30 Tablets)

This is a label for Plavix, a medication used to prevent blood clots. The label indicates that this is the 75 mg dosage in tablet form, and this is a 30-day supply. The manufacturer is Sanofi, and this particular batch was packaged by DOH Central Pharmacy in Tallahassee, Florida. The UPC code is also provided for identification purposes.*

FDA Label Image

Chemical Structure (Plavix 01)

FDA Label Image

Figure (Plavix 02)

FDA Label Image

Figure (Plavix 03)

The text describes a chart showing the cumulative event rate for cardiovascular death, myocardial infarction, and stroke for a group of patients treated with placebo and aspirin versus a group treated with Plavix and aspirin. The chart shows that the Plavix and aspirin group had a significantly lower event rate than the placebo group (P=0.00009). The chart is labeled with the months of follow-up and shows rates up to 12 months. Other standard therapies were used as appropriate in both groups.*

FDA Label Image

Figure (Plavix 04)

This is a table of Baseline Characteristics of individuals taking PLAVIX and Placebo. The table contains data on variables such as diagnosis, age, gender, race, and concomitant medication. The Hazard Ratio (95% Cl) is also included in the table.*

FDA Label Image

Figure (Plavix 05)

The text describes the number of deaths before first discharge in a medical study where a group of patients were given either a placebo or clopidogrel. The results show that the group given clopidogrel had a 7% reduction in risk compared to the placebo group. The data includes a graph showing the number of days since randomization and the percentage of deaths for each group.*

FDA Label Image

Figure (Plavix 06)

The given text contains statistical data regarding the effect of Tiopldogrel on patients. It shows that Tiopldogrel led to a 9% proportional risk reduction compared to Placebo, with only 2121 patients experiencing an event (9.2%). The data is presented in a graph showing the number of days since randomization, up to 28 days. The text suggests that it is related to medical discharges.*

FDA Label Image

Figure (Plavix 07)

FDA Label Image

Figure (Plavix 08)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.